Pulmonary hypertension (PH) represents
|
|
- Herbert Wilfred Quinn
- 5 years ago
- Views:
Transcription
1 Mædica - a Journal of Clinical Medicine MAEDICA a Journal of Clinical Medicine 2014; 9(2): CASE REPORTS Complete Therapeutical Approach in Pulmonary Arterial Hypertension: from Vasodilators to Lung Transplantation - Case Report Tudor CONSTANTINESCU a ; Miron Alexandru BOGDAN a a Marius Nasta Institute of Pneumology, Bucharest, Romania ABSTRACT We present the case of a 37 years old patient with idiopathic pulmonary arterial hypertension (PAH). After initial treatment with calcium channel blockers (CCB), based on a positive vasoreactive response at right heart catheterization, due to disease progression, major vasodilator therapies were introduced in a sequential strategy: sildenafil, bosentan and treprostinil. Finally, the patient received double-lung transplantation with eventually favourable evolution despite immediate postoperative significant complications. Markers of disease progression were monitored before the transplant, and after the intervention the patient was screened according to a specific protocol for bronchiolitis obliterans and infections. According to our knowledge, this case represents a premiere in Romanian medicine, being the first lung transplant in a PAH patient. This case represents a model of PAH with a documented evolution of 8 years. We present the progression of the disease and the effective therapeutic strategies according to the current guidelines. This case reinforces the need for upgrading the Romanian National PAH Program with the inclusion of prostanoid therapy, as an option for severe patients. Keywords: pulmonary arterial hypertension, pulmonary vasoreactive test, vasodilator combination therapy, lung transplantation INTRODUCTION Pulmonary hypertension (PH) represents a heterogeneous family of disorders, characterized by a mean pulmonary arterial pressure (mpap) above 25 mmhg, determined by right heart catheterization (RHC). According to the latest clinical classification, Dana Point 2008, pulmonary arterial hypertension (Group 1), groups a number of rare diseases characterized by precapillary PH (pulmonary wedge pressure, PWP <15 mmhg), with similar clinical picture and similar pathological changes in the Address for correspondence: Tudor Constantinescu, Marius Nasta Institute of Pneumology, 4 th Department of Pneumology, 90 Viilor Avenue, 5 th District, , Bucharest, Romania. tudor_constantinescu@yahoo.com Article received on the 6 th of April Article accepted on the 18 th of June Maedica A Journal of Clinical Medicine, Volume 9 No
2 pulmonary circulation. Idiopathic PAH ac - counts for almost 40% of the PAH group (1,2). Epidemiologic data suggest a PAH prevalence between 15 cases/ million (French registry) to 50 cases / million (Scottish registry) and an incidence of 2.4 cases/ million / year (3,4). The condition is marked by a severe prognosis with an estimation of mean survival, without treatment, of 2.8 years from diagnosis (5). Recent data from the French cohort confirm a 3 year survival of only 67% in the treated population (6). The therapeutic options consist of medical treatments (7-13) and surgical interventions (Table 1). They imply a step-up approach from monotherapy to sequential combination therapy (prostanoids and oral medication), according to markers of disease progression: clinical NYHA functional class (New York Heart Association Classification) and syncope, exercise tolerance 6 minute walking test (6MWT) and cardiopulmonary exercise testing, echocardiography - pericardial effusion, tricuspid annular plane systolic excursion (TAPSE) and right atrial (RA) enlargement, brain natriuretic peptide (BNP) levels and ultimately cardiac output and right atrial pressure on RHC (1,2). CASE REPORT We present the case of a female patient, 37 years old (at diagnosis), non-smoker, active nurse, without previous significant medical history. The first medical presentation was in 2005 for progressive dyspnoea on exertion, for the past 2 years, and recently associated with syncope. The clinical evaluation identified a NYHA functional class III and a modified clinical examination with mild lower limb oedema and the presence of a systolic tricuspid murmur. Cardiac ultrasound revealed a significant pulmonary hypertension (estimated systolic PAP of 97 mmhg) with enlarged right heart chambers (RA 46 mm and RV 42 mm), normal left heart and paradoxical interventricular septum motion. The etiological evaluation was done according to the PH classification, Venice 2003 (14). A thorough diagnostic workup evaluated the 4 major PH groups: chronic thromboembolic PH, hypoxic PH and left heart disease were ruled out and from the PAH Group 1, neither an associated condition nor a familial form were identified, with a final diagnosis of idiopathic PAH. RHC confirmed the pulmonary hypertension: spap 100 mmhg, dpap 31 mmhg, mpap 60 mmhg with a cardiac index (CI) of 2.4l/min/ m 2. The vasodilator test with ilomedin decreased the mpap to 39 mmhg. According to the guidelines (14), a positive test is defined by a lowering of mpap with more than 10 mmhg and below 40mmHg without a decrease of cardiac output, and signals a probability for clinical response to CCB. Diltiazem was introduced and uptitrated to high doses with good clinical benefit and tolerance. At her first visit in our clinic, in 2005, the patient was clinically stable, functional class I, with complete remission of symptoms soon after CCB introduction. The clinical examination showed absence of tachycardia and preserved systemic blood pressure. The 6MWT distance at that time was 582m and lung function tests confirmed normal volumes and flows with only a mild decrease of DLCO to 61% of predictive. The chest radiograph showed a typical pattern of PAH without cardiomegaly (Figure 1A). The ECG presented sinus rhythm, P pulmonale RA strain, right QRS deviation and RV strain. The clinical evolution was marked by disease progression. After 8 months of CCB therapy, the patient presented a clinical deterioration to FC III and also an episode of syncope on exertion and thus she was considered a nonresponder to CCB therapy. The treatment was switched to sildenafil 25 mg TID with a transitory clinical aggravation. After 4 months of persistent FC III, treatment was upgraded to double oral therapy, adding bosentan 125 mg BID, with good clinical and hepatic tolerance. In 2008 a marked clinical aggravation occurred, with dyspnoea at rest, repeated syncopes on mild exertion and overt right heart failure. The patient was admitted to the intensive-care unit and treatment was started with high doses of intravenous furosemide and dobutamine. Due to this major clinical deterioration, in a PAH patient on a double oral vasodilators combination, we considered the remaining therapeutic options: prostanoid treatment and listing for lung transplantation. Balloon atrial septostomy, another possible surgical intervention, was not considered in this case. This procedure is available only in a few experienced centres, none in Romania; it offers only a short relief in symptoms for some selected patients Maedica A Journal of Clinical Medicine, Volume 9 No
3 FIGURE 1. Chest radiograph; A. chest radiograph at diagnosis: arrows pointing inward show the marked enlargement of both main pulmonary arteries with right lower lobe artery diameter more than 16mm and arrows pointing outwards showing the clear lung fields corresponding to olighemia in the peripheral pulmonary circulation; B. chest radiograph after 4 years of disease progression with marked increase of cardiac index due to severe dilatation of the right heart chambers (see difference between initial cardiac index, upper arrow, and final cardiac index, lower arrow). and might be used as a bridge to transplant for NYHA IV patients with severe syncopal symptoms. FIGURE 2. Evolution of 6MWT distance and NYHA functional class following the sequential increase in therapy Treprostinil was started (by continuous subcutaneous pump injection) with a slow uptitration process, permitting the weaning of inotropes and the switch to oral diuretics. Presence of local side effects pain on infusion site was the major issue for dose-progression. At the same time the case was presented to the Vienna (Austria) transplant team. After obtaining the required approvals, the patient was listed for double-lung transplantation. The triple vasodilator therapy induced a mild amelioration to FC III. Due to the plateauing of treprostinil to 10 ng/min/kg because of side effects, the patient deteriorated further. The patient was evaluated periodically before the transplant intervention. The parameters that correlated well with the clinical status were 6MWT distance which decreased steadily to a value of 280 m, and NYHA functional class, which progressed from FC I to FC IV (Figure 2). Also, a good correlation was observed with investigations that monitored the dilatation of the heart, such as chest radiograph (Figure 1B.), showing significant increase of cardiac index, or echocardiography, with dilation of RA and RV. Among parameters that showed no correlation with disease progression we emphasise DLCO and estimation of spap from the velocity of the tricuspid regurgitant jet, parameters which were fairly stable for the entire period. On echocardiography and computed tomography (CT) severity markers were the pre- 200 Maedica A Journal of Clinical Medicine, Volume 9 No
4 sence of pericardial effusion and ascites and major dilation of the RA. In addition, there were no arguments for veno-occlusive disease noted on the CT (lung parenchyma septal lines and nodules, mediastinal adenopathies). Unfortunately RHC was not available for followup. The indication for lung transplantation was established according to international standards (15) and was based on disease progression despite triple therapy, young age and disease severity, with survival estimated to less than 2 years. Our patient required an extensive list of investigations for inclusion on a lung-transplant list, according to the the practice of the transplant center (AKH Vienna) and international recommendations. The workup detailed the specific etiology and lung function and it also evaluated the complete medical status of the patient (screening for possible contra-indications Table 2). For the donor-recipient compatibility the main parameters were blood group and thoracic morphometric measurements. The HLA typing and the presence of anti-hla antibodies may indicate the risk of organ rejection. Due to significant deconditioning, we recommended the inclusion in a local rehabilitation program before the transplantation in order to improve survival. In March 2010 lung transplantation was performed and vasodilator treatment was stopped. The transplant procedure was performed in Vienna General Hospital. According to the protocol for PAH patients, extra-corporeal membrane oxygenator (ECMO) was used during the intervention. The postoperative evolution was difficult due to poor clinical status at the time of the operation, with 9 days of mechanical ventilation, 35 days in the intensivecare unit, haemodialysis for renal failure and gas troparesis. A rehabilitation protocol was implemented when the patient was able to perform physical exercise and the patient was discharged after 4 months in a stable clinical con dition. Treatment after lung transplantation used immunosuppressive drugs (mycophenolate mo fetil, tacrolimus and prednisone), and infection prophylaxis (valganciclovir for CMV and inhaled amphotericin for aspergillus). Functional follow-up included screening for bronchiolitis obliterans syndrome and also bronchial biopsies aiming to detect both organ rejection and chronic lung infection. Groups Classical vasodilators Modern vasodilators (8) Surgical procedures Molecular pathways Drugs Calcium-channel Nifedipine, blockers (CCB) (7) diltiazem, amlodipine Prostacyclin Endothelin receptor antagonists Epoprostenol (9), treprostinil, iloprost, beraprost Bosentan (10), ambrisentan (11), macitentan Nitric oxide (NO) Sildenafil (12), tadalafil (13), riociguat Lung-transplantation (1,2) cases with no contraindications Refractory PAH and CTEPH Atrial septostomy Bridge to transplant or contraindications for lungtransplant TABLE 1. Current treatment options in PAH. Indications General indications - Age <55 years, recommended - Estimated survival <2 years 3 years after lung transplantation, the patient is in stable clinical status with persistence of moderate microcytic anaemia, chronic renal failure with stable creatinine levels, and mild restrictive pattern on pulmonary function tests. The pulmonary hypertension relapse is not an issue and the severe remodelated heart, with important dilation and hypertrophy of the right chambers and compression of the left ventricle, presents a reverse remodelling process. DISCUSSION Idiopathic PAH is a complex and severe disease that requires a specific investigational protocol. The diagnosis implies a multidisciplinary team and should be performed in dedicated centres. RHC is required for diagnosis and also should be used for severity evaluation. Indications PAH with positive vasodilator test NYHA II-IV, PAH and selected Chronic Th romboembolic PH (CTEPH) cases Contraindications Absolute contraindications - Neoplasia active / recent - Severe hepatic / renal failure - B, C hepatitis virus or HIV infection - Anomalies of the thoracic wall - Addiction / severe psychiatric disease Specific indications Relatives contraindications - Progressive disease despite - Extreme BMI (>30/ <18kg/m 2 ) maximal therapy (prostanoids - Colonization with resistant in PAH) bacteria/ fungi / mycobacteria - NYHA functional class III-IV - Severe osteoporosis TABLE 2. Indications and exclusions for lung transplantation (15). Maedica A Journal of Clinical Medicine, Volume 9 No
5 Due to low survival in naïve patients and persistence of increased mortality in treated patients, follow-up parameters such as clinical data NYHA functional class and syncope, 6MWT, echocardiography and ideally RHC are very important. DLCO and PAP are not markers of disease progression. CCB are indicated only in positive vasoreactive patients and should be continued only in responders (approx. 7% of all PAH patients). Vasodilator treatment may require combination therapy in patients with disease progression. New therapies should be added not switched, in order to avoid the risk of rebound. Sequential treatment strategy (1,2), validated in clinical trials, is usually recommended. In patients with markers of severity at baseline combination treatment may be started up-front. All major treatments used by the presented patient (sildenafil, bosentan and treprostinil), were started as donations, due to lack of therapeutic options in Romania at that time. Starting 2008, the patient received sildenafil and bosentan through the Romanian National Program for PAH. Presently, in Romania, over 50 patients receive double oral combination therapy and almost half of them still present markers of severity. Treprostinil and all other prostanoids are still not available in Romania. There is no indication for heart-lung transplant even in cases of severe heart failure. Lung transplantation is still not performed in Romania, although it represents the ultimate option for severe young patients with PAH and other lung diseases. According to our knowledge, this case represents a premiere in Romanian medicine, being the first lung transplant for a PAH patient. CONCLUSION This case represents a model of PAH with a documented evolution of 8 years. We present the progression of the disease and the effective therapeutic strategies according to the current guidelines. This case reinforces the need for upgrading the Romanian National PAH Program with the inclusion of prostanoid therapy as an option for severe patients. Conflict of interests: I undersign, certificate, that I was a consultant, speaker and investigator in clinical studies for Actelion, Pfizer and Glaxo- Smithklein companies. The present presentation was not the subject of a sponsorship. Financial support: none declared. Acknowledgement: I, Tudor Constantinescu, on behalf of all authors of this work, would like to acknowledge the important medical contribution to this clinical case to the following medical teams: - Marius Nasta Institute of Pneumology, Bucharest: Dr. Mona Sara Mitrache, Dr. Dragos Zaharia, Dr. Claudia Toma, Dr. Cornelia Tudose, Dr. Stefan Dumitrache-Rujinski, Dr. Dragos Bumbacea. - Sf. Gheorghe General Hospital: Dr. Livia- Maria Terza. - Tg. Mures Regional Hospital: Professor Imre Benedek. - National Institute of Cardiology, Budapest: Professor Jozsef Borbola. - Vienna General Hospital: The pulmonary transplantation team and especially to Professor Walter Klepetko, Dr. Patrick Nierlich. REFERENCES 1. Galiè N Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009; 30: Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54:S43-S54 3. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: Peacock AJ, Murphy NF, McMurray JJV, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30: D Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: Humbert M, Sitbon O, Yaïci A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36: Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic PAH. Circulation 2005; 111: Humbert M, Sitbon O, Simonneau S Treatment of pulmonary arterial hypertension; N Engl J Med 2004; 351: Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary 202 Maedica A Journal of Clinical Medicine, Volume 9 No
6 hypertension; J Am Coll Cardiol 2002; 40: Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension. Circulation 2008; 117: Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: Galiè N, Brundage BH, Ghofrani HA, et al. Pulmonary arterial hypertension and response to Tadalafil study group. Circulation 2009; 119: Galie N, Torbicki A, Barst R, et al. ESC Guidelines on diagnosis and treatment of pulmonary arterial hypertension. European Heart J 2004; 25; ASTP/ATS/ERS/ISHLT International guidelines for the selection of lung transplant candidates. Am J Respir Crit Care Med 1998; 158: Maedica A Journal of Clinical Medicine, Volume 9 No
National Horizon Scanning Centre. Tadalafil for pulmonary arterial hypertension. October 2007
Tadalafil for pulmonary arterial hypertension October 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationPulmonary Hypertension: When to Initiate Advanced Therapy. Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University
Pulmonary Hypertension: When to Initiate Advanced Therapy Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University Disclosures Medtronic, Abbott: Consultant Hemodynamic Definition of
More informationAnjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced
Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced Heart Failure & Cardiac Transplant Temple University
More informationCardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON
Cardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON Dunbar Ivy, MD The Children s s Hospital Heart Institute 1 Diagnostic Evaluation: Right Heart Cardiac
More informationTeaching Round Claudio Sartori
Teaching Round 14.03.2017 Claudio Sartori Cas clinique Femme 47 ans, connue pour un BPCO, asthénie, douleurs thoraciques, dyspnée à l effort, œdèmes membres inférieurs, deux syncopes. Tabac, BMI 31 kg/m2
More informationThe Case of Lucia Nazzareno Galiè, M.D.
The Case of Lucia Nazzareno Galiè, M.D. DIMES Disclosures Consulting fees and research support from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly and Co, GlaxoSmithKline and Pfizer Ltd Clinical
More informationPharmacy Management Drug Policy
SUBJECT: Pulmonary Arterial Hypertension (PAH) POLICY NUMBER: Pharmacy-42 Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed
More informationNavigating the identification, diagnosis and management of pulmonary hypertension using the updated ESC/ERS guidelines
Navigating the identification, diagnosis and management of pulmonary hypertension using the updated ESC/ERS guidelines Host: Marc Humbert Speaker: Simon Gibbs Marc HUMBERT, MD, PhD Professor of Respiratory
More informationReal-world experience with riociguat in CTEPH
Real-world experience with riociguat in CTEPH Matthias Held Center of Pulmonary Hypertension and Pulmonary Vascular Disease, Medical Mission Hospital, Würzburg, Germany Tuesday, 29 September ERS International
More informationPulmonary Hypertension in 2012
Pulmonary Hypertension in 2012 Evan Brittain, MD December 7, 2012 Kingston, Jamaica VanderbiltHeart.com Disclosures None VanderbiltHeart.com Outline Definition and Classification of PH Hemodynamics of
More informationOral Therapies for Pulmonary Arterial Hypertension
Oral Therapies for Pulmonary Arterial Hypertension Leslie Wooten, PharmD PGY2 Internal Medicine Pharmacy Resident University of Cincinnati Medical Center April 30 th, 2018 Objectives Pharmacist Objectives
More informationThe Case of Marco Nazzareno Galiè, M.D.
The Case of Marco Nazzareno Galiè, M.D. DIMES Disclosures Consulting fees and research support from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly and Co, GlaxoSmithKline and Pfizer Ltd Clinical
More informationPharmacy Management Drug Policy
SUBJECT: POLICY NUMBER: PHARMACY-42 EFFECTIVE DATE: 6/2005 LAST REVIEW DATE: 4/19/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not covered
More informationAdvances in Pharmacotherapy of PAH
24 th Annual Advances in Heart Disease Advances in Pharmacotherapy of PAH Gabriel Gregoratos, MD 12/14/2007 UCSF Cardiology 1 Faculty Disclosure Statement for Gabriel Gregoratos, MD Nothing to disclose
More informationDr. J. R. Rawal 1 ; Dr. H. S. Joshi 2 ; Dr. B. H. Roy 3 ; Dr. R. V. Ainchwar 3 ; Dr. S. S. Sahoo 3 ; Dr. A. P. Rawal 4 ; Dr. R. A.
(6) EFFECT OF ORAL SILDENAFIL ON RESIDUAL PULMONARY ARTERIAL HYPERTENSION IN PATIENTS FOLLOWING SUCCESSFUL PERCUTANEOUS BALLOON MITRAL VALVULOPLASTY (PBMV): SHORT TERM RESULTS IN 12 PATIENTS. Dr. J. R.
More informationTHERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines
THERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines Vu Nang Phuc, MD Dinh Duc Huy, MD Pham Nguyen Vinh, MD, PhD, FACC Tam Duc Cardiology Hospital Faculty Disclosure No conflict of interest
More informationTherapeutic approaches in P(A)H and the new ESC Guidelines
Therapeutic approaches in P(A)H and the new ESC Guidelines Jean-Luc Vachiéry, FESC Head Pulmonary Vascular Diseases and Heart Failure Clinic Hôpital Universitaire Erasme Université Libre de Bruxelles Belgium
More informationDr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college
Dr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college PULMONARY HYPERTENSION Difficult to diagnose early Because Not detected during routine physical examination and Even in advanced cases symptoms
More informationRecent Treatment of Pulmonary Artery Hypertension. Cardiology Division Yonsei University College of Medicine
Recent Treatment of Pulmonary Artery Hypertension Cardiology Division Yonsei University College of Medicine Definition Raised Pulmonary arterial pressure (PAP) WHO criteria : spap>40 mmhg NIH Criteria
More informationPULMONARY ARTERIAL HYPERTENSION AGENTS
Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Adcirca tadalafil Calendar Year Adempas riociguat Calendar Year Flolan epoprostenol sodium Calendar
More informationBosentan for treatment of pulmonary arterial hypertension (I)
KEY PAPER EVALUATION Bosentan for treatment of pulmonary arterial hypertension (I) Sabina A Antoniu University of Medicine and Pharmacy, Clinic of Pulmonary Disease, 62 Costache Negri St, Bl.C2, Sc.A,
More informationPulmonary Hypertension Drugs
Pulmonary Hypertension Drugs Policy Number: Original Effective Date: MM.04.028 10/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/22/2015 Section: Prescription Drugs
More informationUpdate in Pulmonary Arterial Hypertension
Update in Pulmonary Arterial Hypertension Michael J Sanley, MD April 12, 2018 Disclosures I have nothing to disclose 2 1 Case Presentation 67 yo male with atrial fibrillation, CLL on IVIG, presents with
More informationPulmonary Arterial Hypertension: The Approach to Management in 2019
Pulmonary Arterial Hypertension: The Approach to Management in 2019 Munir S. Janmohamed M.D. FACC Medical Director Mechanical Circulatory Support/Heart Failure Program Mercy General Hospital/Mercy Medical
More information1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca)
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutic
More informationPharmacy Management Drug Policy
SUBJECT: POLICY NUMBER: PHARMACY-42 EFFECTIVE DATE: 6/2005 LAST REVIEW DATE: 10/1/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not covered
More informationPatient Case. Patient Case 6/1/2013. Treatment of Pulmonary Hypertension in a Community
Treatment of Pulmonary Hypertension in a Community Hospital Serena Von Ruden, PharmD, RN, BSN St. Francis Hospital Federal Way, WA Franciscan Health System HPI: 66 year old male with advanced oxygendependent
More informationProgress in PAH. Gerald Simonneau
Progress in PAH Gerald Simonneau National Reference center for Pulmonary Hypertension Bicetre University Hospital, INSERM U 999 Paris-Sud University Le Kremlin Bicêtre France Clinical Classification of
More informationChronic Thromboembolic Pulmonary Hypertention CTEPH
Chronic Thromboembolic Pulmonary Hypertention CTEPH Medical Management Otto Schoch, Prof. Dr. Klinik für Pneumologie und Schlafmedizin Kantonsspital St.Gallen CTEPH: Medical Management Diagnostic aspects
More informationACCP PAH Medical Therapy Guidelines: 2007 Update. David Badesch, MD University of Colorado School of Medicine Denver, CO
ACCP PAH Medical Therapy Guidelines: 2007 Update David Badesch, MD University of Colorado School of Medicine Denver, CO Disclosure of Commercial Interest Dr. Badesch has received grant/research support
More informationAddition of Prostanoids in Pulmonary Hypertension Deteriorating on Oral Therapy
Addition of Prostanoids in Pulmonary Hypertension Deteriorating on Oral Therapy Wouter Jacobs, MD, a Anco Boonstra, MD, PhD, a J. Tim Marcus, PhD, b Pieter E. Postmus, MD, PhD, a and Anton Vonk-Noordegraaf,
More informationNational Horizon Scanning Centre. Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class III. April 2008
Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class April 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationWhere are we now in the longterm. of PAH and CTEPH? Hits and misses of medical treatment. Hap Farber Boston University School of Medicine, Boston, USA
Where are we now in the longterm management of PAH and CTEPH? Hits and misses of medical treatment Hap Farber Boston University School of Medicine, Boston, USA Monday, 28 September ERS International Congress
More informationLong-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy
Eur Respir Rev 2009; 18: 114, 253 259 DOI: 10.1183/09059180.00003109 CopyrightßERSJ Ltd 2009 REVIEW Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy
More informationΠνευμονική Υπέρταση Ι.Ε. ΚΑΝΟΝΙΔΗΣ
Πνευμονική Υπέρταση Ι.Ε. ΚΑΝΟΝΙΔΗΣ PH is defined as PAPm 25 mm Hg at rest The general definition of PH remains unchanged Most of the relevant epidemiological and therapeutic studies have used the 25 mm
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Drugs for the treatment of Draft remit / appraisal objective: Draft scope To appraise the clinical and cost effectiveness
More informationPulmonary Hypertension Perioperative Management
Pulmonary Hypertension Perioperative Management Bruce J Leone, MD Professor of Anesthesiology Chief, Neuroanesthesiology Vice Chair for Academic Affairs Mayo Clinic Jacksonville, Florida Introduction Definition
More informationRaymond L. Benza, MD, a Mardi Gomberg-Maitland, MD, MSc, b Robert Naeije, MD, PhD, c Carl P. Arneson, MStat, d and Irene M.
http://www.jhltonline.org Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled
More information2012 CADTH Symposium. April 2012
2012 CADTH Symposium Using Mixed Treatment Comparisons to compare Oral Treatments for Pulmonary Arterial Hypertension and Inform Policy Decisions by a Public Drug Plan April 2012 Objective of this Presentation
More informationPulmonary Hypertension Drugs
Pulmonary Hypertension Drugs Policy Number: Original Effective Date: MM.04.028 10/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO 05/25/2012 Section: Prescription Drugs Place(s) of Service:
More informationUpdates in Pulmonary Hypertension Pharmacotherapy. Ziad Sadik PharmD BCPS
Updates in Pulmonary Hypertension Pharmacotherapy Ziad Sadik PharmD BCPS Disclosure Information I have no financial relationship to disclose AND I will not discuss off label use and/or investigational
More informationPulmonary Hypertension Essentials. PD Dr. med. Silvia Ulrich Somaini University Hospital of Zurich
Pulmonary Hypertension Essentials PD Dr. med. Silvia Ulrich Somaini University Hospital of Zurich Agenda Basics and Presentation Classification Diagnosis Pathogenesis Diagnosis Treatment Pathogenesis and
More informationSA XXXX Special Authority for Subsidy
SA XXXX Special Authority for Subsidy Special authority approved by the Pulmonary Arterial Hypertension (PAH) Panel. Application forms can be obtained from PHARMAC s website: www.pharmac.govt.nz or: PAH
More informationPulmonary arterial hypertension. Pulmonary arterial hypertension: newer therapies. Definition of PH 12/18/16. WHO Group classification of PH
Pulmonary arterial hypertension Pulmonary arterial hypertension: newer therapies Ramona L. Doyle, MD Clinical Professor of Medicine, UCSF Attending Physician UCSF PH Clinic Definition and classification
More informationPulmonary Hypertension: Another Use for Viagra
Pulmonary Hypertension: Another Use for Viagra Kathleen Tong, MD Director, Heart Failure Program Assistant Clinical Professor University of California, Davis Disclosures I have no financial conflicts A
More informationELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY
ELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY Contents Eligibility criteria for Pulmonary Arterial Hypertension therapy...2-6 Initial Application for funding of Pulmonary Arterial Hypertension
More informationClinical Policy: Macitentan (Opsumit) Reference Number: ERX.SPMN.88
Clinical Policy: (Opsumit) Reference Number: ERX.SPMN.88 Effective Date: 07/16 Last Review Date: 06/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationEffective Strategies and Clinical Updates in Pulmonary Arterial Hypertension
Effective Strategies and Clinical Updates in Pulmonary Arterial Hypertension Hap Farber Director, Pulmonary Hypertension Center Boston University School of Medicine Disclosures 1) Honoria: Actelion, Gilead,
More informationADVANCED THERAPIES FOR PHARMACOLOGICAL TREATMENT OF PULMONARY HYPERTENSION
Status Active Medical and Behavioral Health Policy Section: Medicine Policy Number: II-107 Effective Date: 04/21/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members
More informationPulmonary arterial hypertension (PAH) is
Eur Respir Rev 21; 19: 118, 314 32 DOI: 1.1183/95918.781 CopyrightßERS 21 REVIEW Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease
More informationRole of Combination PAH Therapies
Role of Combination PAH Therapies Ronald J. Oudiz, MD, FACP, FACC Associate Professor of Medicine, David Geffen School of Medicine at UCLA Director, Liu Center for Pulmonary Hypertension Los Angeles Biomedical
More informationPulmonary Arterial Hypertension - Overview
Pulmonary Arterial Hypertension - Overview J. Shaun Smith, MD Co-Director, Pulmonary Vascular Disease Program Assistant Professor of Medicine Division of Pulmonary, Critical Care and Sleep Medicine The
More informationPulmonary Arterial Hypertension - Overview
Pulmonary Arterial Hypertension - Overview J. Shaun Smith, MD Co-Director, Pulmonary Vascular Disease Program Assistant Professor of Medicine Division of Pulmonary, Critical Care and Sleep Medicine The
More informationThe need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension
REVIEW 6MWD IN PAH TRIALS The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension Sean Gaine 1 and Gérald Simonneau 2 Affiliations: 1 National Pulmonary Hypertension
More informationIn focus The paediatric PAH population Clinicians Perspectives
In focus The paediatric PAH population Clinicians Perspectives Maurice Beghetti Pediatric Cardiology University Children s Hospital HUG and CHUV Pulmonary Hypertension Program HUG Centre Universitaire
More informationDisclosures. Inhaled Therapy in Pediatric Pulmonary Hypertension. Inhaled Prostacyclin: Rationale. Outline
Disclosures Inhaled Therapy in Pediatric Pulmonary Hypertension The University of Colorado receives fees for Dr Ivy to be a consultant for Actelion, Gilead, Lilly, Pfizer, and United Therapeutics Dunbar
More informationCombination therapy in the treatment of pulmonary arterial hypertension 2015 update
Journal of Rare Cardiovascular Diseases 2015; 2 (4): 103 107 www.jrcd.eu REVIEW ARTICLE Rare diseases of pulmonary circulation Combination therapy in the treatment of pulmonary arterial hypertension 2015
More informationPULMONARY ARTERIAL HYPERTENSION : CURRENT CONCEPTS
3 : 11 PULMONARY ARTERIAL HYPERTENSION : CURRENT CONCEPTS Pulmonary arterial hypertension is a progressive, symptomatic, and ultimately fatal disorder. It can be simply defined as a syndrome characterized
More informationUntreated idiopathic pulmonary arterial hypertension
Congenital Heart Disease Outcomes in Children With Idiopathic Pulmonary Arterial Hypertension Delphine Yung, MD; Allison C. Widlitz, MS, PA; Erika Berman Rosenzweig, MD; Diane Kerstein, MD; Greg Maislin,
More informationIntravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension
Eur Respir J 2002; 20: 339 343 DOI: 10.1183/09031936.02.02462001 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Intravenous iloprost for
More informationUpdates on Pulmonary Hypertension Treatment
Updates on Pulmonary Hypertension Treatment Dane Mellgren, PharmD PGY-1 Pharmacy Practice Resident Hennepin County Medical Center 04/27/18 Disclosure I have no disclosures to be made regarding the content
More informationIV PGI2 vs. Inhaled PGI2 in chronic lung disease
Inhaled Therapies for PAH Erika Berman Rosenzweig, MD Associate Professor of Clinical Pediatrics (in Medicine) Director, Pulmonary Hypertension Center Columbia University Medical Center Disclosures Has
More informationPrognostic value of echocardiographic parameters in patients with pulmonary arterial hypertension (PAH) treated with targeted therapies
Prognostic value of echocardiographic parameters in patients with pulmonary arterial hypertension (PAH) treated with targeted therapies E. Beciani, M. Palazzini, C. Bachetti, F. Sgro, E. Conficoni, E.
More informationSelection of Infusion Prostacyclin Therapy in Pulmonary Arterial Hypertension: Not Just a Last Resort
Selection of Infusion Prostacyclin Therapy in Pulmonary Arterial Hypertension: Not Just a Last Resort Robert Schilz, DO, PhD, FCCP Medical Director, Lung Transplantation and Pulmonary Vascular Disease
More informationTREPROSTINIL Generic Brand HICL GCN Exception/Other TREPROSTINIL REMODULIN 23650
Generic Brand HICL GCN Exception/Other TREPROSTINIL REMODULIN 23650 SODIUM TREPROSTINIL TYVASO 36537 36539 36541 TREPROSTINIL ORENITRAM 40827 **Please use the criteria for the specific drug requested**
More informationPulmonary Hypertension: Follow-up in adolescence and adults
Pulmonary Hypertension: Follow-up in adolescence and adults Helmut Baumgartner Westfälische Wilhelms-Universität Münster Adult Congenital and Valvular Heart Disease Center University of Muenster Germany
More informationTreatment of Paediatric Pulmonary Hypertension
Treatment of Paediatric Pulmonary Hypertension Dunbar Ivy, MD The Children s Hospital Heart Institute University of Colorado School of Medicine 1 Disclosures I have the following financial relationships
More informationSerial Plasma Brain Natriuretic Peptide Testing in Clinical Management of Pulmonary Arterial Hypertension
Original Article Acta Cardiol Sin 2009;25:147 53 Pulmonary Hypertension Serial Plasma Brain Natriuretic Peptide Testing in Clinical Management of Pulmonary Arterial Hypertension Wan-Jing Ho, 1 Tsu-Shiu
More informationPulmonary arterial hypertension (PAH) is a
Eur Respir J 2007; 30: 1103 1110 DOI: 10.1183/09031936.00042107 CopyrightßERS Journals Ltd 2007 A USA-based registry for pulmonary arterial hypertension: 1982 2006 T. Thenappan, S.J. Shah, S. Rich and
More informationClinical Policy: Ambrisentan (Letairis) Reference Number: ERX.SPMN.84 Effective Date: 07/16
Clinical Policy: (Letairis) Reference Number: ERX.SPMN.84 Effective Date: 07/16 Last Review Date: 06/16 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationCONUNDRUMS IN PULMONARY ARTERIAL HYPERTENSION
CONUNDRUMS IN PULMONARY ARTERIAL HYPERTENSION MOHAMMED RAFIQUE ESSOP MILPARK HOSPITAL and UNIVERSITY OF THE WITWATERSRAND POINTS FOR DISCUSSION What is the pathogenetic mechanism of PAH? Importance of
More informationAbstract Book. Inspiring Approaches to Clinical Challenges in Pulmonary Hypertension
Inspiring Approaches to Clinical Challenges in Pulmonary Hypertension Abstract Book A symposium sponsored by Bayer Schering Pharma at ERS 2008 Annual Congress www.ventavis.com Welcome Dear Colleague, It
More informationPulmonary Hypertension. Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes
Pulmonary Hypertension Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes Pulmonary Arterial Hypertension Disease of small pulmonary arteries Characteristic changes Medial hypertrophy Intimal
More informationMedical Therapy for Pulmonary Arterial Hypertension* Updated ACCP Evidence-Based Clinical Practice Guidelines
CHEST Clinical Practice Guidelines Medical Therapy for Pulmonary Arterial Hypertension* Updated ACCP Evidence-Based Clinical Practice Guidelines David B. Badesch, MD, FCCP; Steven H. Abman, MD; Gerald
More informationPulmonary arterial hypertension (PAH) is a. How to detect disease progression in pulmonary arterial hypertension REVIEW
Eur Respir Rev 212; 21: 123, 4 47 DOI: 1.1183/95918.911 CopyrightßERS 212 REVIEW How to detect disease progression in pulmonary arterial hypertension J-L. Vachiéry, P. Yerly and S. Huez ABSTRACT: Pulmonary
More informationContreversies in the management of PH What is controversial in treatment?
Contreversies in the management of PH What is controversial in treatment? Service de Pneumologie et Réanimation National reference center for pulmonary hypertension Université Paris Sud Hôpital Antoine
More informationEffects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension
Journal of the American College of Cardiology Vol. 46, No. 4, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.01.066
More informationPulmonary Hypertension. Murali Chakinala, M.D. Washington University School of Medicine
Pulmonary Hypertension Murali Chakinala, M.D. Washington University School of Medicine Pulmonary Circulation Alveolar Capillary relationship Pulmonary Circulation High flow, low resistance PVR ~1/15 of
More informationOptimal management of severe pulmonary arterial hypertension
Eur Respir Rev 2011; 20: 122, 254 261 DOI: 10.1183/09059180.00007011 CopyrightßERS 2011 REVIEW Optimal management of severe pulmonary arterial hypertension O. Sitbon and G. Simonneau ABSTRACT: Over the
More informationSinus venosus atrial septal defect in a 31- year-old female patient: a case for surgical repair
Eur Respir Rev 2010; 19: 118, 340 344 DOI: 10.1183/09059180.00007610 CopyrightßERS 2010 CASE REPORT Sinus venosus atrial septal defect in a 31- year-old female patient: a case for surgical repair M.A.
More informationProstacyclin has potent vasodilatory,
Eur Respir Rev 29; 18: 111, 29 34 DOI: 1.1183/95918.11111 CopyrightßERSJ Ltd 29 Inhaled iloprost for the treatment of pulmonary hypertension H. Olschewski ABSTRACT: Prostacyclin and its analogues (prostanoids)
More informationSATELLITE SYMPOSIUM OF MSD. sgc Stimulation for the treatment of PH. Real life management of PAH: case presentation
SATELLITE SYMPOSIUM OF MSD sgc Stimulation for the treatment of PH Real life management of PAH: case presentation Eftychia Demerouti MD, MSc, PhD Cardiologist Onassis Cardiac Surgery Center Conflict of
More informationTadalafil for the Treatment of Pulmonary Arterial Hypertension
Journal of the American College of Cardiology Vol. 60, No. 8, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.05.004
More informationClinical Characteristics and Survival of Korean Idiopathic Pulmonary Arterial Hypertension Patients Based on Vasoreactivity
ORIGINAL ARTICLE Respiratory Diseases http://dx.doi.org/10.3346/jkms.2014.29.12.1665 J Korean Med Sci 2014; 29: 1665-1671 Clinical Characteristics and Survival of Korean Idiopathic Pulmonary Arterial Hypertension
More informationTreprostinil-Based Therapy in the Treatment of Moderate-to-Severe Pulmonary Arterial Hypertension* Long-term Efficacy and Combination With Bosentan
CHEST Treprostinil-Based Therapy in the Treatment of Moderate-to-Severe Pulmonary Arterial Hypertension* Long-term Efficacy and Combination With Bosentan Raymond L. Benza, MD; Barry K. Rayburn, MD; Jose
More informationΔΙΑΓΝΩΣΗ ΚΑΙ ΘΕΡΑΠΕΙΑ ΤΗΣ ΧΡΟΝΙΑΣ ΘΡΟΜΒΟΕΜΒΟΛΙΚΗΣ ΥΠΕΡΤΑΣΗΣ (CTEPH)
Aristotle University of Thessaloniki Cardiology Clinic, AHEPA Hospital ΔΙΑΓΝΩΣΗ ΚΑΙ ΘΕΡΑΠΕΙΑ ΤΗΣ ΧΡΟΝΙΑΣ ΘΡΟΜΒΟΕΜΒΟΛΙΚΗΣ ΥΠΕΡΤΑΣΗΣ (CTEPH) Charalampos I. Karvounis, MD Professor of Cardiology Aristotle
More informationPULMONARY HYPERTENSION
PULMONARY HYPERTENSION MARTIN T. MPE CARDIOLOGIST MEDICLINIC HEART HOSPITAL CASE REPORT A 35 year old female, general worker. Married with 2 children with the youngest aged 12 years. Presenting complaints
More informationThe growing interest in pulmonary hypertension (PH) in
Eur Respir J 2010; 36: 986 990 DOI: 10.1183/09031936.00038410 CopyrightßERS 2010 EDITORIAL Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed N. Galiè, M. Palazzini and
More informationFunctional Class and Targeted Therapy Are Related to the Survival in Patients with Pulmonary Arterial Hypertension
Original Article http://dx.doi.org/10.3349/ymj.2014.55.6.1526 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 55(6):1526-1532, 2014 Functional Class and Targeted Therapy Are Related to the Survival in
More informationEffectively treating patients with pulmonary hypertension: The next chapter. Lowering PAP will improve RV function in PH
Effectively treating patients with pulmonary hypertension: The next chapter Stuart Rich, M.D. Hemodynamic Progression of PAH Preclinical Symptomatic/ Stable Pulmonary Pressure Progressive/ Declining Level
More informationPulmonary hypertension on. Simon MacDonald BSc(Hons) BMBCh DPhil FRCP Consultant Cardiologist in Adult Congenital Heart Disease
Pulmonary hypertension on echowhat next.? Simon MacDonald BSc(Hons) BMBCh DPhil FRCP Consultant Cardiologist in Adult Congenital Heart Disease Definition of PAH Mean PA pressure 25mmHg Precapillary if
More informationPulmonary Hypertension: Evolution and
Management of Pulmonary Hypertension: Evolution and Controversies VERMONT CARDIAC NETWORK SPRING CONFERENCE MAY 10, 2018 MARYELLEN ANTKOWIAK, MD, PULMONARY & CRITICAL CARE MEDICINE, UVMMC WHO classification
More informationPulmonary Arterial Hypertension (PAH) Treatments
Care1st Health Plan Arizona, Inc. Easy Choice Health Plan Harmony Health Plan of Illinois Missouri Care Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona OneCare (Care1st Health
More informationNothing to Disclose. Severe Pulmonary Hypertension
Severe Ronald Pearl, MD, PhD Professor and Chair Department of Anesthesiology Stanford University Rpearl@stanford.edu Nothing to Disclose 65 year old female Elective knee surgery NYHA Class 3 Aortic stenosis
More information22nd Annual Heart Failure 2018 an Update on Therapy. Pulmonary Arterial Hypertension: Contemporary Approach to Treatment
22nd Annual Heart Failure 2018 an Update on Therapy Pulmonary Arterial Hypertension: Contemporary Approach to Treatment Ronald J. Oudiz, MD, FACP, FACC, FCCP Professor of Medicine The David Geffen School
More informationImage: Patrick J. Lynch, Wikimedia Commons
Image: Patrick J. Lynch, Wikimedia Commons Victor J. Samillan 1,2 Andrew J. Peacock 1 1 Scottish Pulmonary Vascular Unit, Golden Jubilee National Hospital, Glasgow, UK 2 Dept of Human Physiology, Medical
More informationoriginal article Directing therapy in pulmonary arterial hypertension using a target 6 min walk distance
Directing therapy in pulmonary arterial hypertension using a target 6 min walk distance Nancy Rose Porhownik MD, Renelle Myers MD, Zoheir Bshouty MD PhD NR Porhownik, R Myers, Z Bshouty. Directing therapy
More informationRiociguat for chronic thromboembolic pulmonary hypertension
Riociguat for chronic thromboembolic pulmonary hypertension This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationManaging Multiple Oral Medications
Managing Multiple Oral Medications Chris Archer-Chicko, MSN, CRNP PENN Presbyterian Medical Center Arlene Schiro,, CRNP Massachusetts General Hospital Mary Bartlett, CRNP Winthrop University Hospital PH
More information